Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationInterferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Research works printed but not linked: 2
- Brockman MA Blood 2009 114 346 19365081 PMC2714209 · DOI · Paper page
- 10.1089/jir.2012.0037 · DOI
Cited by
Items 201–300 of 713
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 68
Sex differences in HIV-1-mediated immunopathology
Ziegler, S. M., & Altfeld, M. A. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000237 · Cited by 71
“Although blocking of IFNa during acute infection had detrimental consequences on the outcome of the LCMV infection, blocking of IFNa during chronic LCMV infection allowed for enhanced immune control [68,69].”
BackgroundShaabani, N., Duhan, V., Khairnar, V., Gassa, A., Ferrer-Tur, R., Häussinger, D., Recher, M., Zelinskyy, G., Liu, J., Dittmer, U., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.350 · Cited by 67
“2,3 9 IL-10 and PD-L1 are important inhibitors of CD8 + T cells and thereby limit the function of virus-specific CD8 + T cells.”
A Dual Role of Type I Interferons in Antitumor Immunity
Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 64
Macrophage and T Cell Produced IL-10 Promotes Viral Chronicity
Richter, K., Perriard, G., Behrendt, R., Schwendener, R. A., Sexl, V., Dunn, R., Kamanaka, M., Flavell, R. A., Roers, A., & Oxenius, A. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003735 · Cited by 63
“It was recently shown that splenic DCs treated in vitro with type I IFN produce IL10 [24] and that anti-IFNR1 blockade led to reduced numbers of IL-10 PD-L1 immunoregulatory DCs which in turn stimulated elevated numbers of IFN-c CD4 T cells and a decrease in viral titers [54].”
BackgroundSuppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection
Yamada, D. H., Elsaesser, H. J., Lux, A., Timmerman, J. M., Morrison, S. L., de la Torre, J. C., Nimmerjahn, F., & Brooks, D. G. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.005 · Cited by 65
“…suppression of other Ab functions such as effective target binding, receptor blockade (Barber et al., 2006; Brooks et al., 2006; Teijaro et al., 2013; Wilson et al., 2013), or neutralization of infectious virus, suggesting that the non-Fc g R-medi-ated functions of Abs might not be affected.”
Self-citationCallendret, B., Eccleston, H. B., Hall, S., Satterfield, W. C., Capone, S., Folgori, A., Cortese, R., Nicosia, A., & Walker, C. M. (2014) · Hepatology · doi:10.1002/hep.27278 · Cited by 63
“This cytokine that is sometimes necessary for CD8(1) T-cell differentiation,(21-23) but under some circumstances also limits effector function or survival(24-29) and contributes to virus persistence in murine models.(30,31) With oral dosing, a shorter duration of therapy, and reduced toxicity of direct-acting antivira…”
BackgroundLanna, A., Coutavas, E., Levati, L., Seidel, J., Rustin, M. H. A., Henson, S. M., Akbar, A. N., & Franzese, O. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301409 · Cited by 62
“It has been suggested that this may be a control mechanism that limits immunopathology that may arise from chronic stimulation in tissues (6, 60, 61).”
Wang, D., Fu, B., Shen, X., Guo, C., Liu, Y., Zhang, J., Sun, R., Ye, Y., Li, J., Tian, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00776-0 · Cited by 65
Khan, S. M., Desai, R. R., Coxon, A. T., Livingstone, A. J., Dunn, G. P., Petti, A. A., & Johanns, T. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005293 · Cited by 64
Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice
Ayala, A. V., Hsu, C.-Y., Oles, R. E., Matsuo, K., Loomis, L. R., Buzun, E., Terrazas, M. C., Gerner, R. R., Lu, H.-H., Kim, S., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230063 · Cited by 66
“Further, tonic type I IFN expression is essential for effective T cell responses (Aman et al., 1996; Levings et al., 2001; Bilsborough et al., 2003; Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundPharmacological Inhibition of Type I Interferon Signaling Protects Mice Against Lethal Sepsis
Dejager, L., Vandevyver, S., Ballegeer, M., Wonterghem, E. V., An, L.-L., Riggs, J. M., Kolbeck, R., & Libert, C. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit600 · Cited by 62
“Accordingly, blocking type I IFN signaling also clears persistent viral infections [31, 32].”
BackgroundSuperoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage
Bhattacharya, A., Hegazy, A. N., Deigendesch, N., Kosack, L., Cupovic, J., Kandasamy, R. K., Hildebrandt, A., Merkler, D., Kühl, A. A., Vilagos, B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.013 · Cited by 60
“As shown previously in Figure 7, the blockade of IFNAR1 resulted in protection from early hepatitis, yet it subsequently led to exacerbated concentrations of ALT 12 days after infection, coinciding with improved virus control that was likely driven by T cells (Figure S5C) (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundInfluentialRoselli, F., Chandrasekar, A., & Morganti-Kossmann, M. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00458 · Cited by 60
“In a different setting involving the comparison of acute and chronic LCMV infection, suppression of type-I IFN signaling by deletion of the Ifnar gene (which encodes the IFN receptor shared by all type-I IFNs) ameliorates the clearing of the LCMV and the resolution of the inflammatory response through a mechanism requ…”
BackgroundNice, T. J., Osborne, L. C., Tomov, V. T., Artis, D., Wherry, E. J., & Virgin, H. W. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005684 · Cited by 61
Cell-Cell Sensing of Viral Infection by Plasmacytoid Dendritic Cells
Webster, B., Assil, S., & Dreux, M. (2016) · Journal of Virology · doi:10.1128/jvi.01692-16 · Cited by 57
“For instance, in a mouse model of chronic LCMV infection, long-term type I IFN-mediated immunosuppression was found to be associated with the induction of inhibitory signals that switch the antiviral regulation by type I IFNs during the acute phase of infection to a proviral function at the chronic stage (19, 20).”
BackgroundConfounding roles for type I interferons during bacterial and viral pathogenesis
Carrero, J. A. (2013) · International Immunology · doi:10.1093/intimm/dxt050 · Cited by 68
“The presence of IFN-I is associated with a prolonged signature of interferon-inducible genes in spleen cells (38) .”
BackgroundTeijaro, J. R., Studer, S., Leaf, N., Kiosses, W. B., Nguyen, N., Matsuki, K., Negishi, H., Taniguchi, T., Oldstone, M. B. A., & Rosen, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525356113 · Cited by 59
“Proc Natl Acad Sci USA 106(5):1560–1565.”
Shepardson, K. M., Larson, K., Morton, R. V., Prigge, J. R., Schmidt, E. E., Huber, V. C., & Rynda‐Apple, A. (2016) · mBio · doi:10.1128/mbio.00506-16 · Cited by 61
CD4+ T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective
Vella, L. A., Herati, R. S., & Wherry, E. J. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.001 · Cited by 69
Taylor, J. P., Cash, M. N., Santostefano, K. E., Nakanishi, M., Terada, N., & Wallet, M. A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mia0917-352r · Cited by 60
Protozoan Parasites and Type I IFNs
Silva‐Barrios, S., & Stäger, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00014 · Cited by 68
He, R., Yang, X., Liu, C., Chen, X., Wang, L., Xiao, M., Ye, J., Wu, Y., & Ye, L. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.3 · Cited by 62
Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL
Kannagi, M., Hasegawa, A., Nagano, Y., Kimpara, S., & Suehiro, Y. (2019) · Retrovirology · doi:10.1186/s12977-019-0484-z · Cited by 64
STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments
Guerini, D. (2022) · Cells · doi:10.3390/cells11071159 · Cited by 58
“Although the cGAS/STING pathway activation is considered one of the first defenses that the immune system deploys to fight against viral infection, once the acute phase is terminated, elevated type I interferon has been shown to propagate chronic inflammation that damages tissue and prevents tissue recovery [45,46].”
BackgroundImmune Cells Link Obesity-associated Type 2 Diabetes and Periodontitis
Zhu, M., & Nikolajczyk, B. S. (2014) · Journal of Dental Research · doi:10.1177/0022034513518943 · Cited by 62
Xu, X., Qiu, C., Zhu, L., Huang, J., Li, L., Fu, W., Zhang, L., Wei, J., Wang, Y., Geng, Y., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401249 · Cited by 55
“Overall, IFN-a and ISGs together may indeed play an important role in the elimination of pathogens during early infection, but these players may ultimately aid the pathogens during chronic infection as suggested by the association of IFN-I and CD4 T cell depletion in a humanized mice model (12, 13, 56).”
BackgroundClement, M., Marsden, M., Stacey, M. A., Abdul-Karim, J., Brias, S. G., Bento, D. F. C., Scurr, M. J., Ghazal, P., Weaver, C. T., Carlesso, G., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006050 · Cited by 57
Willemsen, J., Wicht, O., Wolanski, J., Baur, N., Bastian, S., Haas, D. A., Matula, P., Knapp, B. L., Meyniel‐Schicklin, L., Wang, C., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.021 · Cited by 63
Interferon regulatory factor 3 in adaptive immune responses
de Lendonck, L. Y., Martinet, V., & Goriely, S. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1653-9 · Cited by 61
“In the context of chronic LCMV infection, these effects are detrimental to the host and participate in virus persistence by generating “hyper-immune” activation [85, 86].”
TET3 Inhibits Type I IFN Production Independent of DNA Demethylation
Xue, S., Liu, C., Sun, X., Li, W., Zhang, C., Zhou, X., Lu, Y., Xiao, J., Li, C., Xu, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.068 · Cited by 59
Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon
Akiyama, H., Ramirez, N.-G. P., Gibson, G. A., Kline, C. E., Watkins, S. C., Ambrose, Z., & Gummuluru, S. (2017) · Journal of Virology · doi:10.1128/jvi.00972-17 · Cited by 57
Macal, M., Jo, Y., Dallari, S., Chang, A. Y., Dai, J., Swaminathan, S., Wehrens, E. J., Fitzgerald-Bocarsly, P. A., & Zúñiga, E. I. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.020 · Cited by 56
“on days 2, 4, and 6 post-LCMV Cl13 infection as previously described (Wilson et al., 2013).”
Boukhaled, G. M., Gadalla, R., Elsaesser, H. J., Abd-Rabbo, D., Quevedo, R., Yang, S. Y. C., Guo, M., Wang, B. X., Noamani, B., Gray, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01262-7 · Cited by 59
Self-citationCai, B., Wu, J., Yu, X. H., Su, X., & Wang, R.-F. (2017) · mBio · doi:10.1128/mbio.02161-16 · Cited by 57
Racicot, K. E., Aldo, P. B., El-Guindy, A. S., Kwon, J., Romero, R. J., & Mor, G. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601824 · Cited by 57
“Type I IFN, through the IFN-a/b receptor (IFNAR), induces a multitude of IFNstimulated genes that can block viral replication and activate the immune system in response to the virus (34, 35).”
BackgroundCrosby, E. J., Clark, M. L., Novais, F. O., Wherry, E. J., & Scott, P. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500855 · Cited by 54
The viral innate immune antagonism and an alternative vaccine design for PRRS virus
Ke, H., & Yoo, D. (2017) · Veterinary Microbiology · doi:10.1016/j.vetmic.2017.03.014 · Cited by 59
“In contrast, recent studies show that the LCMV persistence in mice is controlled or lost when type I IFN signaling is blocked, demonstrating the paradoxical role of type I IFNs in viral persistence (Teijaro et al., 2013; Wilson et al., 2013).”
Escobar, G., Barbarossa, L., Barbiera, G., Norelli, M., Genua, M., Ranghetti, A., Plati, T., Camisa, B., Brombin, C., Cittaro, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05315-0 · Cited by 55
Type I Interferons and Malaria: A Double-Edge Sword Against a Complex Parasitic Disease
He, X., Xia, L., Tumas, K. C., Wu, J., & Su, X. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.594621 · Cited by 57
“, 2014) andmediate immunosuppression during chronic viral infections (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundImmune Exhaustion and Transplantation
Fueyo, A. S., & Markmann, J. F. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13702 · Cited by 53
Presentation of hepatocellular antigens
Grakoui, A., & Crispe, I. N. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.109 · Cited by 57
Taleb, K., Auffray, C., Villefroy, P., Pereira, A. L., Hosmalin, A., Gaudry, M., & Bon, A. L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502638 · Cited by 53
“suppression found in this infection at onset of infection (5, 6).”
BackgroundInfluentialRegulation of autoimmune and anti‐tumour T‐cell responses by PTPN 22
Brownlie, R. J., Zamoyska, R., & Salmond, R. J. (2018) · Immunology · doi:10.1111/imm.12919 · Cited by 63
“Excessive production of type 1 IFN following infection can result in T cell exhaustion (54, 55).”
BackgroundTLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women
Azar, P., Mejía, J. E., Cénac, C., Shaiykova, A., Youness, A., Laffont, S., Essat, A., Izopet, J., Passaes, C., Müller-Trutwin, M. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136047 · Cited by 57
“Here, blockade of IFN-I signalling, induced even before infection, promoted viral clearance (17, 18).”
BackgroundZemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 55
Puttur, F. K., Arnold‐Schrauf, C., Lahl, K., Solmaz, G., Lindenberg, M., Mayer, C. T., Gohmert, M., Swallow, M., van Helt, C., Schmitt, H., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003648 · Cited by 54
“role and induce negative immune regulation as recently described [52,53].”
BackgroundInterferon–microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis
Yang, Y., Lin, X., Lu, X., Luo, G., Zeng, T., Tang, J. P., Jiang, F., Li, L., Cui, X., Huang, W., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310318 · Cited by 56
Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action
Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 57
Cytokines and persistent viral infections
Beltra, J., & Decaluwe, H. (2016) · Cytokine · doi:10.1016/j.cyto.2016.02.006 · Cited by 55
Jiang, L., Yao, S., Huang, S., Wright, J., Braciale, T. J., & Sun, J. (2016) · European Journal of Immunology · doi:10.1002/eji.201646548 · Cited by 51
DDX3 suppresses type I interferons and favors viral replication during Arenavirus infection
Loureiro, M. E., Zorzetto-Fernandes, A. L., Radoshitzky, S. R., Chī, X., Dallari, S., Marooki, N., Léger, P., Foscaldi, S., Harjono, V., Sharma, S., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007125 · Cited by 55
The integrated stress response mediates necrosis in murine Mycobacterium tuberculosis granulomas
Bhattacharya, B., Xiao, S., Chatterjee, S., Urbanowski, M. E., Ordoñez, A. A., Ihms, E. A., Agrahari, G., Lun, S., Berland, R., Pichugin, A. V., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci130319 · Cited by 53
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 56
Transcriptional and epigenetic regulation of T cell hyporesponsiveness
Pereira, R. M., Hogan, P. G., Rao, A., & Martinez, G. J. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ri0317-097r · Cited by 46
Scagnolari, C., & Antonelli, G. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.03.003 · Cited by 50
“Indeed, a direct causal link between type I IFN signaling, immune activation, negative immune regulator expression (e.g. IL-10 and PD-L1), lymphoid tissue disorganization, impaired humoral responses to secondary viral infection, and persistent LCMV has been reported [6] [7] [8] [9] .”
The uric acid crystal receptor Clec12A potentiates type I interferon responses
Li, K., Neumann, K., Duhan, V., Namineni, S., Hansen, A. L., Wartewig, T., Kurgyis, Z., Holm, C. K., Heikenwälder, M. F., Lang, K. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821351116 · Cited by 52
“However, during chronic LCMV infection, prolonged IFN-I signaling can facilitate virus persistence by inducing the expression of negative immune regulators, such as programmed death-ligand 1 and IL-10 (15, 16).”
BackgroundInfluentialIL-10: Achieving Balance During Persistent Viral Infection
Ng, C. T., & Oldstone, M. B. A. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-43492-5_6 · Cited by 52
“Infection with both ARM and CL-13 initiates the production of IFNα in the first 24 h (Teijaro et al. 2013; Wilson et al. 2013).”
BackgroundPérez-Girón, J. V., Belicha‐Villanueva, A., Hassan, E., Gómez‐Medina, S., Cruz, J. L. G., Lüdtke, A., Ruibal, P., Albrecht, R. A., García‐Sastre, A., & Muñoz‐Fontela, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400222 · Cited by 49
“We hypothesized that this may be due to inflammation-dependent protection of viral replication (33, 34), a common phenomenon in the upper respiratory tract that is especially relevant in the context of influenza and bacterial coinfections (35).”
BackgroundPlanès, R., Haij, N. B., Leghmari, K., Serrero, M. C., BenMohamed, L., & Bahraoui, E. (2016) · Journal of Virology · doi:10.1128/jvi.00262-16 · Cited by 50
The Role of IFN-β during the Course of Sepsis Progression and Its Therapeutic Potential
Rackov, G., Shokri, R., Álvarez‐Mon, M., Martínez‐A, C., & Balomenos, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00493 · Cited by 54
“IFNα/β can nonetheless have detrimental immunosuppressive effects during chronic infection with certain viruses (56, 57).”
BackgroundDagenais-Lussier, X., Loucif, H., Murira, A., Laulhé, X., Stäger, S., Lamarre, A., & van Grevenynghe, J. (2017) · Viruses · doi:10.3390/v10010012 · Cited by 49
“IFNR blockade also increases total splenic T-lymphocyte and antiviral specific CD4 T-cell numbers during LCMVCL13 infection [26,29,63].”
BackgroundInfluentialChronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitness
Isringhausen, S., Mun, Y., Kovtonyuk, L. V., Kräutler, N. J., Suessbier, U., Gomariz, Á., Spaltro, G., Helbling, P. M., Wong, H. C., Nagasawa, T., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20192070 · Cited by 51
“Nonetheless, recent work has shown that in the context of persistent viral infections, exacerbated IFN production contributes to CD8 exhaustion, establishment of chronic states of immune activation, and destruction of lymphoid tissue microarchitecture (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundMethodIn Vitro and In Vivo Characterizations of Pichinde Viral Nucleoprotein Exoribonuclease Functions
Huang, Q., Shao, J., Lan, S., Zhou, Y., Xing, J., Dong, C., Liang, Y., & Ly, H. (2015) · Journal of Virology · doi:10.1128/jvi.00009-15 · Cited by 49
Dahlgren, M. W., Plumb, A. W., Niss, K., Lahl, K., Brunak, S., & Johansson‐Lindbom, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932388 · Cited by 52
“The LCMV clone 13 strain establishes a persistent infection where long-lasting expression of IFN-b and IFN-a in cDCs leads to exhaustion of the protective Th1 cell response by a mechanism involving up-regulation of PD-L1 and IL-10 expression by the cDCs (57, 58).”
BackgroundNew insights into type I interferon and the immunopathogenesis of persistent viral infections
Snell, L. M., & Brooks, D. G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.03.002 · Cited by 51
Self-citationPTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection
Maine, C. J., Teijaro, J. R., Marquardt, K., & Sherman, L. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603738113 · Cited by 50
“Quantitation of IL-10 in the serum and cell-culture supernatants was carried out using the Quantikine IL-10 ELISA kit according to the manufacturer’s instructions (R&D Systems).”
BackgroundInfluentialOliviero, B., Mantovani, S., Varchetta, S., Mele, D., Grossi, G., Ludovisi, S., Nuti, E., Rossello, A., & Mondelli, M. U. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.032 · Cited by 46
Huber, M., Suprunenko, T., Ashhurst, T. M., Marbach, F., Raifer, H., Wolff, S., Strecker, T., Viengkhou, B., Jung, S. R., Obermann, H.-L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01219-17 · Cited by 47
“Note that recent studies have shown that in contrast to the early antiviral response, where IFN-I are required for virus control and elimination, prolonged IFN-I responses during chronic infection contribute to CD8 T cell exhaustion (40, 41).”
ResultMenicucci, A. R., Versteeg, K. M., Woolsey, C. B., Mire, C. E., Geisbert, J. B., Cross, R. W., Agans, K. N., Jankeel, A., Geisbert, T. W., & Messaoudi, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01372 · Cited by 50
“A recent study showed production of immunosuppressive mediators IL-10 and PD-L1 is dependent on Type I IFN signaling in a mouse model of lymphocytic choriomeningitis virus infection (68, 69).”
BackgroundThe role of type I interferons in CD4+ T cell differentiation
Kuka, M., Giovanni, M. D., & Iannacone, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.01.013 · Cited by 46
“One interpretation might be that the role of type I IFNs changes based on whether the infection is acute or chronic [10], with interferons supporting CD4+ T cell expansion in the acute phase, but inducing their exhaustion during the chronic phase [29,32,42].”
BackgroundBaral, S., Antia, R., & Dixit, N. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902178116 · Cited by 47
“In other studies, regulatory T cells (8), factors contributing to CD8 T-cell dysfunction (9, 10), type I interferon (IFN) signaling (11, 12), and most recently, host genetics (13) have been argued to influence the outcomes of LCMV infection.”
BackgroundSignaling by Type I Interferons in Immune Cells: Disease Consequences
Ζαννίκου, Μ., Fish, E. N., & Platanias, L. C. (2024) · Cancers · doi:10.3390/cancers16081600 · Cited by 45
“However, by blocking IFN-I signaling with a neutralizing antibody against its receptor, this reduced immune system activation, decreased expression of immune checkpoint molecules, resulting in faster viral elimination [154,155].”
BackgroundTransient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
Broomfield, B. J., Tan, C. W., Qin, R. Z., Abberger, H., Duckworth, B. C., Alvarado, C., Dalit, L., Lee, C. L., Mugan, R. S., Mazrad, Z. A. I., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241148 · Cited by 48
“Although this demonstrates IFN-Is are essential for control of viral infection, chronic induction of IFN-I counteracts positive immune responses to potentiate immune dysfunction (Cheng et al., 2017; Crouse et al., 2015; Marx et al., 2023; Teijaro et al., 2013; Wilson et al., 2013; Wu et al., 2016).”
Dallari, S., Macal, M., Loureiro, M. E., Jo, Y., Swanson, L., Hesser, C. R., Ghosh, P., & Zúñiga, E. I. (2017) · Nature Communications · doi:10.1038/ncomms14830 · Cited by 45
Minkah, N. K., Wilder, B. K., Sheikh, A. A., Martinson, T., Wegmair, L., Vaughan, A. M., & Kappe, S. H. I. (2019) · Nature Communications · doi:10.1038/s41467-019-11819-0 · Cited by 53
Type I IFNs and CD8 T cells increase intestinal barrier permeability after chronic viral infection
Labarta-Bajo, L., Nilsen, S. P., Humphrey, G., Schwartz, T., Sanders, K., Swafford, A. D.-E., Knight, R. D., Turner, J. R., & Zúñiga, E. I. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192276 · Cited by 47
“On the other hand, we observed that type I IFNs limited (rather than promoted) accumulation of virus-specific CD4 T cells in small intestines from chronically infected mice, which is consistent with the type I IFN inhibition of splenic CD4 T cell accumulation that was previously reported (Teijaro et al., 2013; Wilson…”
ResultVersteeg, K. M., Menicucci, A. R., Woolsey, C. B., Mire, C. E., Geisbert, J. B., Cross, R. W., Agans, K. N., Jeske, D. R., Messaoudi, I., & Geisbert, T. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-09963-y · Cited by 44
Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus
Kahan, S. M., & Zajac, A. J. (2019) · Viruses · doi:10.3390/v11020156 · Cited by 48
“IFN-I blockade treatments prior to or during chronic LCMV infection reduces T cell exhaustion and improves viral control [20,161].”
BackgroundReis, A. L., Goatley, L. C., Jabbar, T., López, E., Rathakrishnan, A., & Dixon, L. K. (2020) · Vaccines · doi:10.3390/vaccines8020262 · Cited by 44
“Interestingly, type I IFN has been implicated in the dysregulation of the immune responses during persistent viral infections [17,18].”
BackgroundGetting “Inside” Type I IFNs: Type I IFNs in Intracellular Bacterial Infections
Snyder, D. T., Hedges, J. F., & Jutila, M. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/9361802 · Cited by 49
Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies
Huot, N., Bosinger, S. E., Paiardini, M., Reeves, R. K., & Müller-Trutwin, M. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00780 · Cited by 43
Xu, W., Snell, L. M., Guo, M., Boukhaled, G. M., Macleod, B. L., Li, M., Tullius, M. V., Guidos, C. J., Tsao, M., Divangahi, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.003 · Cited by 45
“Type I interferon (IFN-I) signaling is also enhanced by chronic LCMV infection (Wilson et al., 2013) and although generally considered beneficial to Mtb growth in vivo Xu et al.”
BackgroundSelf-citationMikhalkevich, N., O’Carroll, I. P., Tkavc, R., Lund, K., Sukumar, G., Dalgard, C. L., Johnson, K. R., Li, W., Wang, T., Nath, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009305 · Cited by 44
Bolen, C. R., Robek, M. D., Brodsky, L., Schulz, V., Lim, J. K., Taylor, M. W., & Kleinstein, S. H. (2012) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0037 · Cited by 42
Snell, L. M., Xu, W., Abd-Rabbo, D., Boukhaled, G. M., Guo, M., MacLeod, B., Elsaesser, H. J., Hezaveh, K., Alsahafi, N., Lukhele, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01060-7 · Cited by 46
Self-citationPrevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer
Bauer, C. A., Kühnemuth, B., Duewell, P., Ormanns, S., Gress, T. M., & Schnurr, M. M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.057 · Cited by 45
Lymphotoxin in physiology of lymphoid tissues – Implication for antiviral defense
Koroleva, E. P., Fu, Y., & Tumanov, A. V. (2016) · Cytokine · doi:10.1016/j.cyto.2016.08.018 · Cited by 42
“Persistent LCMV infection and influenza infection are linked with excessive pathogenic production of type I IFN which can induce cytokine storm and thereby promote lung immunopathology [64,118,119].”
Chang, Y.-H., Wang, K. C., Chu, K.-L., Clouthier, D., Tran, A., Perez, M. S. T., Zhou, A. C., Sater, A. A. A., & Watts, T. H. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.014 · Cited by 46
“However, IFN-I signaling is known to persist to the chronic stage of infection (Teijaro et al., 2013;Wilson et al., 2013).”
BackgroundNganou‐Makamdop, K., Billingsley, J. M., Yaffe, Z. A., O’Connor, G., Tharp, G. K., Ransier, A., Laboune, F., Matus‐Nicodemos, R., Lerner, A. M., Gharu, L., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007246 · Cited by 42
“T cell exhaustion is associated with persistent antigenic stimulation; many reports have previously highlighted that chronic type I IFN signaling during viral infections results in CD8 T cell exhaustion [21–23] and have shown that blocking IFN-I signaling restores T cell function in LCMV-infected mice [13, 14, 24].”
BackgroundGreene, T. T., & Zúñiga, E. I. (2021) · Viruses · doi:10.3390/v13091839 · Cited by 42
Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus
Felt, S. A., Moerdyk-Schauwecker, M. J., & Grdzelishvili, V. Z. (2014) · Virology · doi:10.1016/j.virol.2014.10.026 · Cited by 48
“Furthermore, the pattern of ISG expression differs in response to acute virus infection or IFN treatment as compared to chronic virus infection (Li et al., 2014; Wilson et al., 2013) or diseases involving chronic type I IFN production, including some cancers (Cheon et al., 2014).”
A Ceramide Analogue Stimulates Dendritic Cells To Promote T Cell Responses upon Virus Infections
Pritzl, C. J., Seo, Y., Xia, C., Vijayan, M., Stokes, Z. D., & Hahm, B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402672 · Cited by 41
Planès, R., Serrero, M. C., Leghmari, K., BenMohamed, L., & Bahraoui, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-35478-1 · Cited by 40
The Role of Interferon in Persistent Viral Infection: Insights from Murine Norovirus
Nice, T. J., Robinson, B. A., & Winkle, J. A. V. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.010 · Cited by 39
“In two separate studies, transient antibody blockade of IFNAR1 reduced production of the immunosuppressive cytokine, interleukin 10 (IL-10), increased CTL function, and enhanced viral clearance [43,44].”
BackgroundHarker, J. A., Wong, K. A., Dallari, S., Bao, P., Dolgoter, A., Jo, Y., Wehrens, E. J., Macal, M., & Zúñiga, E. I. (2018) · Journal of Virology · doi:10.1128/jvi.02196-17 · Cited by 39
“Signaling through IFN- R is critical for control of LCMV Cl13 persistence, and its absence results in enhanced depletion and exhaustion of virus-specific T cells (49), though sustained IFN-I signaling also has a deleterious effect on T cell responses (18, 19).”
BackgroundElsaesser, H. J., Mohtashami, M., Osokine, I., Snell, L. M., Cunningham, C. R., Boukhaled, G. M., McGavern, D. B., Zúñiga‐Pflücker, J. C., & Brooks, D. G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913776117 · Cited by 40
“We recently identified that type I interferons (IFN-I) lie at the nexus of these two programs, both providing the inflammatory signals necessary to initiate robust immunity, while reciprocally inducing negative regulatory mechanisms that suppress ongoing immune activation (2, 4, 5).”
BackgroundSelf-citationPietro, A. D., Polmear, J., Cooper, L., Damelang, T., Hussain, T., Hailes, L., O’Donnell, K., Udupa, V., Tian, M., Preston, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01077-y · Cited by 42
Sendai Virus Pathogenesis in Mice Is Prevented by Ifit2 and Exacerbated by Interferon
Wetzel, J. L., Fensterl, V., & Sen, G. C. (2014) · Journal of Virology · doi:10.1128/jvi.02201-14 · Cited by 40
“Blocking type I IFN action enabled virus clearance and restoration of a normal state of immune activation (36, 37).”
BackgroundNaigeon, M., Dugage, M. R., Danlos, F., Boselli, L., Jouniaux, J.-M., de Oliveira, C., Ferrara, R., Duchemann, B., Berthot, C., Girard, L., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0708 · Cited by 41
Metadata
- Authors
- Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G.
- Affiliations
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brooks, David G.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 202-207
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3704950
- OpenAlex
- W2049868800
- Cited by
- 709
- References
- 29
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 34 · 2023: 35 · 2022: 35 · 2021: 48 · 2020: 50 · 2019: 50 · 2018: 58 · 2017: 72 · 2016: 87 · 2015: 72 · 2014: 70 · 2013: 34
- FWCI
- 48.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000077)
- National Heart, Lung, and Blood Institute (R01HL108949, HL108949)
- National Institute of Allergy and Infectious Diseases (AI060567, T32AI060567, U01AI082975, R01AI085043, AI082975, R01AI056154, AI085043, R01AI047868, P30AI028697)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR063020)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- type I interferon signaling, chronic infection, lymphocytic choriomeningitis virus, viral persistence, immune activation, immunosuppression, CD4+ T cells, interferon-gamma, antiviral immunity, viral clearance
- MeSH terms
- Animals, Antibodies, Arenaviridae Infections, Dendritic Cells, Immune Tolerance, Interferon Type I, Interferon-gamma, Lymphocytic choriomeningitis virus, Virus Replication, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.